Indivior Plc (INDV)

$24.36 -0.10 (-0.41%)
Market Cap 3.35B
Revenue (ttm) 1.19B
Net Income (ttm) 2.00M
EPS (ttm) N/A
PE Ratio 13.66
Forward PE 15.09
Profit Margin 0.17%
Debt to Equity Ratio -1.27
Volume 2,040,900
Avg Vol 3,156,608
Day's Range N/A - N/A
Shares Out 137.88M
Stochastic %K 91%
Beta 0.74
Analysts Strong Sell
Price Target $25.83

Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorp...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 804 379 1090
Address:
10710 Midlothian Turnpike, Suite 125, North Chesterfield, United States
JarvisFlow
JarvisFlow Aug. 27 at 5:55 PM
Craig-Hallum updates rating for Indivior ( $INDV ) to Buy, target set at 27 → 34.
0 · Reply
kharlus
kharlus Aug. 19 at 9:58 PM
$INDV time for a pullback …
0 · Reply
Doozio
Doozio Aug. 15 at 3:23 PM
$INDV YO so 💪 it appears only chop n shakeouts to come. Hard to see a real correction wen a $PGNY is still chop chop huckleberries getting medicated thru XBI 🐒🍌🧠⏰♾️
0 · Reply
JarvisFlow
JarvisFlow Aug. 6 at 11:30 AM
HC Wainwright & Co. has updated their rating for Indivior ( $INDV ) to Buy with a price target of 28.
0 · Reply
kinderspiel
kinderspiel Aug. 1 at 9:09 PM
$INDV Indivior PLC Price $ 21.05 (+4.2%) Trade Count: 3,635 Total $ 2.88 M (90-Day Avg : 77.4 K) Call $ 2.88 M Put $ 5
0 · Reply
Doozio
Doozio Aug. 1 at 7:04 PM
$INDV why no? This is still a $PGNY 🐒🍌🧠⏰♾️. Fook all da 🐑🐳s. Bums. 🍿
0 · Reply
howardlindzon
howardlindzon Aug. 1 at 6:48 PM
Very american that the ozempic of Oiods is at all-time highs What's left of free markets still works $INDV
0 · Reply
howardlindzon
howardlindzon Aug. 1 at 6:46 PM
$INDV the old opiod trend...Interesting...
0 · Reply
jesys
jesys Aug. 1 at 4:23 PM
$INDV $3O is good with me 😊🦓💰
0 · Reply
ivanhoff
ivanhoff Aug. 1 at 4:12 PM
Interesting names on the new 52-week relative strength high list today - $INDV (treatment of opioid dependence), $MP (rare earth metals), $COOP (mortgages), $NVT (another AI data center component play), etc.
0 · Reply
Latest News on INDV
Indivior to Participate in Upcoming Investor Events

Aug 20, 2025, 12:00 PM EDT - 7 days ago

Indivior to Participate in Upcoming Investor Events

Indivior's Strategic Turnaround Gains Traction Post-Q2 2025

Aug 5, 2025, 5:39 PM EDT - 22 days ago

Indivior's Strategic Turnaround Gains Traction Post-Q2 2025

Indivior PLC (INDV) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 5:22 AM EDT - 26 days ago

Indivior PLC (INDV) Q2 2025 Earnings Call Transcript

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

Jul 31, 2025, 7:00 AM EDT - 27 days ago

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Jul 25, 2025, 2:00 AM EDT - 4 weeks ago

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Jul 23, 2025, 8:00 AM EDT - 5 weeks ago

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

Jul 17, 2025, 9:00 AM EDT - 5 weeks ago

Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

Jul 8, 2025, 8:00 AM EDT - 7 weeks ago

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

Jun 30, 2025, 7:00 AM EDT - 2 months ago

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

Indivior Appoints Tony Kingsley to the Board of Directors

Jun 24, 2025, 4:12 PM EDT - 2 months ago

Indivior Appoints Tony Kingsley to the Board of Directors

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Jun 19, 2025, 9:00 AM EDT - 2 months ago

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Jun 2, 2025, 2:33 AM EDT - 3 months ago

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Jun 2, 2025, 2:00 AM EDT - 3 months ago

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Indivior Announces Patrick Barry as Chief Commercial Officer

May 27, 2025, 8:30 AM EDT - 3 months ago

Indivior Announces Patrick Barry as Chief Commercial Officer

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

May 1, 2025, 10:27 AM EDT - 4 months ago

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

Indivior: Trying To Break Addiction

Apr 28, 2025, 12:12 PM EDT - 4 months ago

Indivior: Trying To Break Addiction

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Apr 24, 2025, 10:45 AM EDT - 4 months ago

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Indivior Announces Q1 2025 Financial Results

Apr 24, 2025, 2:00 AM EDT - 4 months ago

Indivior Announces Q1 2025 Financial Results

Indivior Announces Further Changes to Board of Directors

Mar 4, 2025, 8:40 AM EST - 6 months ago

Indivior Announces Further Changes to Board of Directors

UK's Indivior appoints Joe Ciaffoni as CEO

Feb 27, 2025, 2:48 AM EST - 6 months ago

UK's Indivior appoints Joe Ciaffoni as CEO

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Feb 27, 2025, 2:00 AM EST - 6 months ago

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Feb 24, 2025, 2:00 AM EST - 6 months ago

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:26 PM EST - 6 months ago

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Feb 20, 2025, 2:13 PM EST - 6 months ago

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

UK's Indivior forecasts 17% decline in 2025 revenue

Feb 20, 2025, 2:55 AM EST - 6 months ago

UK's Indivior forecasts 17% decline in 2025 revenue

Indivior Announces FY and Q4 2024 Financial Results

Feb 20, 2025, 2:00 AM EST - 6 months ago

Indivior Announces FY and Q4 2024 Financial Results

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

Feb 12, 2025, 2:00 AM EST - 7 months ago

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Nov 19, 2024, 12:52 PM EST - 10 months ago

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Nov 7, 2024, 2:24 PM EST - 10 months ago

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Oct 30, 2024, 12:30 PM EDT - 10 months ago

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior PLC (INDV) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 2:02 PM EDT - 10 months ago

Indivior PLC (INDV) Q3 2024 Earnings Call Transcript

Indivior Announces Q3 2024 Financial Results

Oct 24, 2024, 2:00 AM EDT - 10 months ago

Indivior Announces Q3 2024 Financial Results

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Oct 13, 2024, 10:00 AM EDT - 11 months ago

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

British drugmaker Indivior cuts 2024 revenue forecast, shares fall

Oct 10, 2024, 7:33 AM EDT - 11 months ago

British drugmaker Indivior cuts 2024 revenue forecast, shares fall

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Oct 10, 2024, 7:00 AM EDT - 11 months ago

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Oct 7, 2024, 11:30 AM EDT - 11 months ago

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

INDV Deadline: Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Sep 29, 2024, 6:01 PM EDT - 11 months ago

INDV Deadline: Rosen Law Firm Urges Indivior PLC (INDV) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Indivior PLC Is Being Sued For Violating Securities Laws And Affected Investors Are Encouraged To Lend A Hand To The Schall Law Firm

Sep 29, 2024, 11:00 AM EDT - 11 months ago

Indivior PLC Is Being Sued For Violating Securities Laws And Affected Investors Are Encouraged To Lend A Hand To The Schall Law Firm

Indivior PLC Is Being Sued For Violating Securities Laws And Investors Are Urged To Assist The Schall Law Firm

Sep 27, 2024, 11:00 AM EDT - 11 months ago

Indivior PLC Is Being Sued For Violating Securities Laws And Investors Are Urged To Assist The Schall Law Firm

JarvisFlow
JarvisFlow Aug. 27 at 5:55 PM
Craig-Hallum updates rating for Indivior ( $INDV ) to Buy, target set at 27 → 34.
0 · Reply
kharlus
kharlus Aug. 19 at 9:58 PM
$INDV time for a pullback …
0 · Reply
Doozio
Doozio Aug. 15 at 3:23 PM
$INDV YO so 💪 it appears only chop n shakeouts to come. Hard to see a real correction wen a $PGNY is still chop chop huckleberries getting medicated thru XBI 🐒🍌🧠⏰♾️
0 · Reply
JarvisFlow
JarvisFlow Aug. 6 at 11:30 AM
HC Wainwright & Co. has updated their rating for Indivior ( $INDV ) to Buy with a price target of 28.
0 · Reply
kinderspiel
kinderspiel Aug. 1 at 9:09 PM
$INDV Indivior PLC Price $ 21.05 (+4.2%) Trade Count: 3,635 Total $ 2.88 M (90-Day Avg : 77.4 K) Call $ 2.88 M Put $ 5
0 · Reply
Doozio
Doozio Aug. 1 at 7:04 PM
$INDV why no? This is still a $PGNY 🐒🍌🧠⏰♾️. Fook all da 🐑🐳s. Bums. 🍿
0 · Reply
howardlindzon
howardlindzon Aug. 1 at 6:48 PM
Very american that the ozempic of Oiods is at all-time highs What's left of free markets still works $INDV
0 · Reply
howardlindzon
howardlindzon Aug. 1 at 6:46 PM
$INDV the old opiod trend...Interesting...
0 · Reply
jesys
jesys Aug. 1 at 4:23 PM
$INDV $3O is good with me 😊🦓💰
0 · Reply
ivanhoff
ivanhoff Aug. 1 at 4:12 PM
Interesting names on the new 52-week relative strength high list today - $INDV (treatment of opioid dependence), $MP (rare earth metals), $COOP (mortgages), $NVT (another AI data center component play), etc.
0 · Reply
LewisDaKat
LewisDaKat Jul. 31 at 7:56 PM
News Expected earnings - Indivior PLC https://marketwirenews.com/news-releases/expected-earnings-indivior-plc-6313548166842440.html $INDV
0 · Reply
XkaliburTrading
XkaliburTrading Jul. 25 at 8:08 AM
$INDV https://www.benzinga.com/pressreleases/25/07/n46623294/indivior-announces-completion-of-cancellation-of-secondary-listing-on-london-stock-exchange-primar
0 · Reply
JarvisFlow
JarvisFlow Jul. 22 at 11:00 AM
Jefferies has adjusted their stance on Indivior ( $INDV ), setting the rating to Buy with a target price of 20.
0 · Reply
JarvisFlow
JarvisFlow Jun. 30 at 1:28 PM
Craig-Hallum updates rating for Indivior ( $INDV ) to Buy, target set at 15 → 22.
0 · Reply
Pootart
Pootart Jun. 28 at 12:04 AM
$INDV 20 million volume today something big is happening
0 · Reply
Doozio
Doozio Jun. 7 at 4:48 PM
$INDV bear to bull 🐒🍌🧠⏰♾️
0 · Reply
jesys
jesys Jun. 6 at 8:00 PM
$INDV strong 💪🚀 have good weekend
0 · Reply
jesys
jesys Jun. 6 at 5:20 PM
$INDV still buying 🙄🦓
0 · Reply
DaddyDipWizard
DaddyDipWizard Jun. 3 at 1:23 PM
$INDV huge dental decay lawsuit incoming. Real problems with medications they’re manufacturing. I’m out.
0 · Reply
jesys
jesys May. 28 at 6:20 PM
$INDV guess timing is right for starting position 😁
1 · Reply
Arcides
Arcides May. 23 at 7:15 PM
$INDV first base above 200dma? still in progress
1 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine May. 1 at 2:32 PM
Indivior ($INDV) releases pivotal pregnancy safety data for SUBLOCADE - no increased risks vs general population in 322 cases. While this expands addressable market, Q1 revenue still down 6.3% YoY and negative equity (-$286M) lingers. Safety profile strengthens but financials remain shaky. https://www.prnewswire.com/news-releases/new-study-highlights-monthly-sublocade-as-a-potential-treatment-option-for-opioid-use-disorder-during-and-after-pregnancy-302444173.html
0 · Reply